This study was aimed to estimate the possible influence of the polymorphisms of GSTs and CYP in the occurrence of CML as well as in predicting therapeutic outcome of nilotinib therapy in Pakistani CML patients. The gene discussed is HPGDS; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.